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Assessing health status over time: impact
of recall period and anchor question on the
minimal clinically important difference of
copd health status tools
H. J. Alma1,2* , C. de Jong1,2, D. Jelusic3, M. Wittmann3, M. Schuler4, B. J. Kollen1, R. Sanderman5,6, K. Schultz3,
J. W. H. Kocks1,2 and T. Van der Molen1,2
Abstract
Background: The Minimal Clinically Important Difference (MCID) assesses what change on a measurement tool can
be considered minimal clinically relevant. Although the recall period can influence questionnaire scores, it is unclear
if it influences the MCID. This study is the first to examine longitudinally the impact of the recall period of an
anchor question and its design on the MCID of COPD health status tools using the COPD Assessment Test (CAT),
Clinical COPD Questionnaire (CCQ) and the St. George’s Respiratory Questionnaire (SGRQ).
Methods: Moderate to very severe COPD patients without respiratory co-morbidities were recruited during 3-week
Pulmonary Rehabilitation (PR). CAT, CCQ and SGRQ were completed at baseline, discharge, 3, 6, 9 and 12 months. A 15-
point Global Rating of Change scale (GRC) was completed at each follow-up. A five-point GRC was used as second
anchor at 12 months. Mean change scores of a subset of patients indicating a minimal improvement on each of the
anchor questions were considered the MCID. The MCID estimates over different time periods were compared with one
another by evaluating the degree of overlap of Confidence Intervals (CI) adjusted for dependency.
Results: In total 451 patients were included (57.9 ± 6.6 years, 65% male, 50/39/11% GOLD II/III/IV), of which 309
completed follow-up. Baseline health status scores were 20.2 ± 7.3 (CAT), 2.9 ± 1.2 (CCQ) and 50.7 ± 17.3 (SGRQ). MCID
estimates for improvement ranged − 3.1 to − 1.4 for CAT, − 0.6 to − 0.3 for CCQ, and − 10.3 to − 7.6 for SGRQ.
Absolute higher – though not significant – MCIDs were observed for CAT and CCQ directly after PR. Significantly
absolute lower MCID estimates were observed for CAT (difference − 1.4: CI -2.3 to − 0.5) and CCQ (difference − 0.2: CI
-0.3 to −0.1) using a five-point GRC.
Conclusions: The recall period of a 15-point anchor question seemed to have limited impact on the MCID for
improvement of CAT, CCQ and SGRQ during PR; although a 3-week MCID estimate directly after PR might lead to
absolute higher values. However, the design of the anchor question was likely to influence the MCID of CAT and CCQ.
Trial registration: RIMTCORE trial #DRKS00004609 and #12107 (Ethik-Kommission der Bayerischen Landesärztekammer).
Keywords: Chronic obstructive pulmonary disease (COPD), Health status, Clinical COPD questionnaire (CCQ), COPD
assessment test (CAT), St. George’s respiratory questionnaire (SGRQ), Minimal clinically important difference, Clinically
relevant change, Global rating of change scale, Recall period, Pulmonary rehabilitation
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Background
Health status can be defined as “the impact of health on a
person’s ability to perform and derive fulfilment from the
activities of daily life” [1]. Its measurement is a standardized
means of quantifying this impact on a patient’s daily life,
health and wellbeing [1, 2]. Multiple general- and
disease-specific health status tools have been developed to
detect and quantify health status [3, 4]. Physiological mea-
sures alone do not reflect the full impact of the disease and
correlations with Health-Related Quality of Life (HRQoL)
are often weak [4]. Determining treatment effects requires
a parameter that assesses to what extent change on a health
status tool can be considered clinically relevant. The
Minimal Clinically Important Difference (MCID) is used to
evaluate this. It has been defined as “the smallest difference
in score, which patients perceive as beneficial and which
would mandate a change in the patient’s management” [5].
Observed change should exceed the estimated MCID value
in order to be clinically relevant.
MCID estimates can be determined using both anchor-
and distribution-based methods [6–8]. A frequently applied
anchor-based technique is the use of a reference (anchor)
question, requiring patients to retrospectively assess their
current health state compared to a prior measurement in
time or their experienced degree of change over time [6–8].
This anchor question usually consists of multiple ordinal
reply options varying from much worse, a little worse, no
change, a little better up to much better [9, 10]. The tech-
nique may also be referred to as patient-referencing [6]. In
the literature, several descriptions are used for this kind of
anchor question: Global Rating scale of Change (GRC), Pa-
tient Global Impression of Change, Global Perceived
Change, Transition Rating Scale and many more [9, 10].
The MCID of a health status instrument can be determined
by calculating the mean change score observed for those
patients indicating a minimal change (little better or little
worse) on the anchor question, assuming data being
normally distributed [9].
The use of these patient rating scales has pros and
cons. Its main strengths are the ease of administration
and MCID determination, as well as the involvement of
a patient-related clinical anchor [9]. However, it remains
unclear over which period of time change on a GRC
should be assessed and how many answering options the
anchor question should include. When assessing change
over a longer period of time, it might be more difficult
for the patient to recall their former health state. A lon-
ger recall period could result in a different MCID [10].
On the other hand, shorter periods of measurement may
not reflect real change. There is no golden standard in
defining an instrument’s MCID [11].
In COPD much focus is nowadays on health status
measurement [12, 13], because spirometry assessment has
only a weak to moderate correlation with the patient’s
wellbeing [14, 15]. The COPD Assessment Test (CAT)
[16], the Clinical COPD Questionnaire (CCQ) [17], and
the St. George’s Respiratory Questionnaire (SGRQ) [18]
are recommended by the Global initiative for Chronic Ob-
structive Lung Disease (GOLD) for the assessment of
COPD in order to determine whether a patient is symp-
tomatic and to what extent therapy has been successful
[19]. CAT and CCQ are most applicable in clinical prac-
tice, and SGRQ in scientific research [19, 20].
Various studies examined the MCID of the CCQ to be
0.40–0.50 [21–26], including three studies using an anchor
question with recall periods ranging from two to three days
[21] up to three weeks [25] and eight weeks [23]. The MCID
of the CAT was estimated to be two to three points [24–28],
of which three studies used an anchor question with recall
periods of three weeks [25] and eight weeks [27, 28]. For the
SGRQ, the MCID of four points is frequently used in clinical
trials. However, estimates in the literature range from four to
eight points [25, 29–31], of which two studies used
patient-referencing techniques with recall periods of three
weeks [25] and sixteen weeks [29, 31]. No studies have
investigated the influence of the recall period of the anchor
question and the number of its ordinal reply categories upon
the MCID of these instruments. Therefore, this study aimed
to investigate the impact of the length of the anchor’s recall
period and the number of reply options on the GRC on the
MCID of the most frequently used health status tools CAT,
CCQ and SGRQ in patients with COPD recruited from a
Pulmonary Rehabilitation (PR) setting.
Patients and methods
Study subjects
The Routine Inspiratory Muscle Training within COPD Re-
habilitation (RIMTCORE) study was a real-life randomized
controlled trial (trial number #DRKS00004609) in the Klinik
Bad Reichenhall, Center for Rehabilitation, Pulmonology and
Orthopedics in Germany [32]. Patients were included be-
tween February 2013 and July 2014. Detailed inclusion- and
exclusion criteria have been published elsewhere [25, 32].
This study is a secondary analysis of a subsample including
COPD participants GOLD II-IV aged ≥18 years, who gave
informed consent, without respiratory co-morbidities (e.g.
bronchiectasis, asthma, history of bronchial carcinoma, sar-
coidosis, tuberculosis), or alpha-1-antitrypsin deficiency.
Study design and data collection
Patients participated in an intensive three-weeks full-day in-
patient rehabilitation program tailored to the patient’s indi-
vidual needs including components of physical training,
education, smoking cessation, physiotherapy and counselling
[25, 32]. Patient characteristics and post-bronchodilator spir-
ometry were collected at baseline and after three weeks at
the end of PR. Primary parameters collected for this
sub-study were the CAT (no recall period), CCQ (weekly
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version) and SGRQ (monthly version) at baseline, discharge
and during follow-up measurements at three, six, nine and
twelve months. Measurements were taken in the clinic be-
fore and after PR. Patients were blinded to their previous an-
swers during PR. The remaining follow-up questionnaires
were sent to the patient’s home by regular mail.
The CAT is an eight-item one-dimensional scale with
item scores ranging from zero to five (zero: no impair-
ment; five: maximum impairment), summing up to a
total of maximum 40 points [16]. The CCQ consists of
ten items scoring from zero to six (zero: no impairment;
six: maximum impairment) [17]. Domain scores (symp-
toms, functional status and mental status) and the total
questionnaire score can be determined by summing all
relevant item scores divided by the number of items.
The SGRQ has 50 items divided over the domains symp-
toms, activities and impact [18]. Scores are calculated
using the developers’ scoring file. Domain and total
SGRQ scores can range from zero to 100 (zero: no im-
pairment, 100: maximum impairment). Scores of CAT
and CCQ were multiplied and standardized into a scale
from zero to 100 to be comparable with SRGQ. All three
questionnaires were validated and reliable in primary
and secondary care, as well as PR for COPD patients
[18, 29, 33, 34]. The tools are recommended according
to the GOLD guidelines [19].
At each follow-up moment a 15-point Likert scale GRC
anchor question was scored by the patient requiring assess-
ment of their global health in relation to COPD compared
with the start of PR (see Additional file 1: Figure S1). An-
swers were marked on a scale from − 7 to + 7, ranging from
very much worse to very much better and zero equalling no
change [9]. At 12-months follow-up a five-point GRC,
analogue to the second question of the SF-36, was also
scored by the patient (see Additional file 1: Figure S2) [35].
It required patients to rate their general health compared
to one year prior. Patients could assess their status as the
same, somewhat better or somewhat worse, or as much bet-
ter ormuch worse. Both GRCs are frequently used in MCID
research [9]. The term recall period in this sense, refers to
the recall period of the GRCs.
Determining the MCID
Scores for CAT, CCQ and SGRQ refer to their total
scores. All change scores on the three questionnaires were
calculated as the difference between baseline and each re-
spective follow-up measurement. Negative change on
these health status tools indicated improvement and posi-
tive change represented deterioration in HRQoL. Changes
on these instruments were categorized using the corre-
sponding score on the GRC anchor question. Scores of 0
and ± 1 on the 15-point GRC indicated no change; scores
of ±2 and ± 3 represented a minimal change; scores of ±4
and ± 5 were summarized as a moderate change; and
scores of ±6 and ± 7 indicated a large change [9]. The
five-point GRC resulted in a division of patients as not
changed, somewhat better, somewhat worse, much better,
or much worse [35]. MCID estimates for the CAT, CCQ
and SGRQ total scores were calculated as the mean
change scores compared with baseline including the 95%
Confidence Interval (95%CI) of those patients indicating a
minimal improvement (+ 2 and + 3) on the GRC at each
follow-up measurement, after checking for normality of
distribution of the data. In addition to the 15-point Likert
GRC scale, the five-point anchor question was used in a
similar way to classify patients as somewhat better. Only
patients that indicated an improvement on the GRC were
included, since patients tend to get better after interven-
tion and a limited number of patients were expected to
deteriorate.
Data analysis
Data analysis was performed using SPSS 23.0 (IBM, Chicago,
USA). Descriptive data were evaluated at baseline for either
frequencies with percentages (%), mean with Standard Devi-
ation (SD) or median with range. This was depending on the
variable characteristics and/or normality of distribution.
CAT, CCQ and SGRQ were evaluated at baseline (T0), at
discharge (T1), after three months (T2), after six months
(T3), after nine months (T4) and after twelve months (T5).
Normality of distribution was assessed using histograms
combined with skewness and kurtosis results. Values be-
tween − 1 and + 1 were considered indicative for normality.
Mean and standard deviations (or median and range) were
calculated for each measurement. Data were checked for
floor- and ceiling effects defined as more than 15% of the pa-
tients in the lowest and highest 10% of the maximum scale
score [36]. All health status change scores were calculated
between baseline and each follow-up measurement. These
change scores were tested for significance using paired
t-tests after verifying normality of distribution. All tests were
assessed for significance using the level p < 0.05.
The MCID determination process included several steps.
First, correlations between the GRC anchor questions, and
the CAT, CCQ or SGRQ were assessed using Pearson or
Spearman correlation coefficients depending on normality
of distribution. Correlations needed to be ≥0.30 (preferably
≥0.50) to be eligible as anchor [7]. Next, participants were
categorized according to their GRC score at each
follow-up measurement. The respective change versus
baseline was tested for significance using paired t-tests
after checking for normality. Each MCID estimate was cal-
culated as the mean change score compared with baseline
including its 95% CI for those patients indicating a min-
imal improvement/somewhat better on the GRC for each
follow-up moment. Correspondence between the 15-point
and five-point GRC was analysed using cross tabulations,
correlation coefficients and bar charts.
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All MCID estimates were tested for significance with one
another by determining the degree of overlap of the adjusted
CIs. Due to the dependency of the data, the Intra Class Cor-
relation Coefficient (ICC) between follow-up measurement
and baseline was calculated and used to construct CIs. Ad-
justed CIs were calculated based on the ICC between
follow-up moment and baseline [37]. The degree of depend-
ency affects the width of the CI required to be able to test
for significant differences between the various MCID esti-
mates. Results were visualized in plots. A lack of overlap be-
tween the MCID estimates and their respective CI indicated
significant differences between MCIDs. Finally, the MCID
estimates and their adjusted CIs from the current study were
also compared with the available thresholds from the litera-
ture (CAT 2.00, CCQ 0.40, and SGRQ 4.00 points).
Results
Patient characteristics
This secondary analysis of the RIMTCORE trial included
451 patients [32]. All patients had completed baseline data
and at discharge, with the exception for one incomplete
CCQ questionnaire, two incomplete CAT questionnaires
and four incomplete SGRQ questionnaires at discharge.
During follow-up 355 patients had completed data after
three months; 319 after six months; 304 after nine months;
and 309 after twelve months (Fig. 1). In total, eight patients
died during follow-up according to our knowledge, 41
dropped out at own request and a varying number of
non-responses at follow-up was present. Mean age was
58 years, 65% was male and had a mean Forced Expiratory
Volume in 1 s % predicted (FEV1%pred) of 50.4 ± 15.1
(Table 1). There were no significant baseline differences be-
tween patients completing the 12-months follow-up and
those who did not. Full patient characteristics at baseline
have been published elsewhere [25].
Health status scores
CAT, CCQ and SGRQ total scores were normally distributed
for all measurement moments between T0 and T5. Com-
pleted pairs of change scores (follow-up vs. baseline) were in-
cluded only (pair-wise deletion). There were no floor- and
ceiling effects observed. There were no significant baseline
differences in health status between complete and incom-
plete follow-up patients (Table 1). Mean baseline scores were
20.2 ± 7.3 (CAT), 2.9 ± 1.2 (CCQ) and 50.7 ± 17.3 (SGRQ)
(Table 1). Mean change after twelve months follow-up was
significant compared with baseline of -0.9 (95% CI -1.7 to
-0.1) for CAT; -0.2 (95% CI -0.3 to -0.1) for CCQ; and -3.9
(95% CI -5.7 to -2.2) for SGRQ (Table 2).
Minimal clinically important differences for CAT, CCQ and
SGRQ
All change scores and 15-point anchor question scores were
normally distributed. The five-point GRC at 12 months was
treated as non-parametric data. At T1, one patient had a
missing GRC score. No other GRC scores were missing for
T2-T5. Correlations between the five-/15-point anchor
questions and the health status change scores on the CAT,
CCQ and SGRQ were all ≥0.30, except for CCQ and CAT
at T1 (Table 3). The Spearman correlation coefficient be-
tween the five- and 15-point GRC at 12 months was
0.81.The overlap between the five-point GRC and 15-point
GRC classification at 12-months was 55% based upon a
cross-tabulation (Fig. 2).
A subset of the total patient population, indicated a min-
imal improvement according to their GRC score. Patients in-
dicating a minimal improvement on the 15-point GRC
(scores of + 2 or + 3) noted significant absolute mean
changes between the start of pulmonary rehabilitation and
twelve months follow-up measurement of − 2.8 (95% CI
−4.2 to − 1.4) on the CAT; − 0.5 (95% CI −0.7 to − 0.3) on
the CCQ; and− 8.8 (95% CI −11.8 to − 5.8) on the SGRQ
(Table 4). MCID estimates ranged from − 3.1 to − 2.3 for
CAT; − 0.6 to − 0.4 for CCQ; and from − 10.3 to − 7.6 for
the SGRQ. Mean change scores of those patients feeling
somewhat better on the five-point GRC after 12 months
were− 1.4 for CAT (95% CI -2.7 to − 0.1), − 0.3 for CCQ
(95% CI −0.5 to − 0.2), and− 7.7 for SGRQ (95% CI −10.5 to
− 4.8) (Table 4).
Tests of significance between MCID estimates
ICC values ranged 0.5–0.7 for CAT, 0.5–0.7 for CCQ,
and 0.6–0.7 for SGRQ (Table 5).
Figures 3 and 4 visually plot the MCID estimates for
CAT, CCQ and SGRQ including their respective adjusted
confidence intervals for each recall period on both GRCs.
Overlap was present for all CAT MCID estimates, except
for the twelve months estimate using the five-point anchor
question compared with the 15-point GRC. A significantly
absolute lower MCID estimate was observed for CAT
using the 5-point GRC (difference −1.4: adjusted CI −2.3
to − 0.5). The MCID measured with the 15-point GRC
over the nine months period as well as the MCID using
the five-point anchor question overlapped with the CAT
estimate from the literature of two points.
The MCID plotted for the CCQ visualized that all esti-
mates with their corresponding CIs overlapped one an-
other, except for the twelve months estimate with the
five-point GRC compared with the 15-point GRC (Fig. 3).
A significantly absolute lower MCID estimate was ob-
served for CCQ using the 5-point GRC at 12 months
(difference − 0.2: CI −0.3 to −0.1). All estimates included
the MCID from the literature of 0.40 points, except for
the three weeks 15-point GRC anchor question estimate.
The plot for the MCID of the SGRQ showed all ranges
overlapping one another, except for the nine months
15-point GRC anchor question method, which was signifi-
cantly different from the three weeks 15-point GRC estimate
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Fig. 1 Consort flow-chart of the number of patients during follow-up
Table 1 Baseline patient characteristics
Baseline all patients
N = 451
Patients with complete follow-up
N = 309
Patients with incomplete follow-up
N = 142
Significance testing
Age (years)a 57.9 ± 6.6 58.1 ± 6.5 57.5 ± 6.6 p = 0.39
Gender (male)b 65.0 63.8 67.6 p = 0.43
FEV1%pred
a 50.4 ± 15.1 50.6 ± 14.9 50.0 ± 15.6 p = 0.72
GOLD IIb 227 (50.3) 158 (51.1) 69 (48.6)
GOLD IIIb 176 (39.0) 121 (39.2) 55 (38.7) p = 0.63
GOLD IVb 48 (10.6) 30 (9.7) 18 (12.7)
Smoking pack years a 42.6 ± 23.5 41.1 ± 23.1 45.9 ± 24.0 p = 0.05
CAT a 20.2 ± 7.3 20.0 ± 7.6 20.8 ± 6.8 p = 0.28
CCQ Totala 2.9 ± 1.2 2.8 ± 1.2 3.0 ± 1.1 p = 0.06
SGRQ Totala 50.7 ± 17.3 49.6 ± 17.8 53.0 ± 16.2 p = 0.05
CAT COPD Assessment Test, CCQ Clinical COPD Questionnaire, FEV1%pred Forced Expiratory Volume in 1 Second % predicted, GOLD Global initiative for Chronic
Obstructive Lung Disease, N Number of Patients, SGRQ St. George’s Respiratory Questionnaire
aData expressed as mean ± SD
bData expressed as frequencies (% of total)
Significance tested with independent t-tests or Chi Square tests at level p < 0.05
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and three months 15-point GRC estimate (Fig. 4). There
were no significant differences between the five-point and
15-point GRC at 12 months. All estimates were significantly
different from the four points estimate in the literature.
Discussion
Summary of main findings
This study found no systematic significant differences be-
tween various recall periods of a 15-point anchor question
on the MCID for improvement of the COPD health status
tools CAT, CCQ and SGRQ in a PR setting. Using this
15-point GRC, MCID estimates for improvement ranged −
3.1 to − 2.3 for CAT; − 0.6 to − 0.4 for CCQ; and − 10.3 to
− 7.6 for SGRQ. Higher absolute MCID estimates were ob-
served for CAT and CCQ with a shorter three weeks recall
period directly after PR, although not significant. The nine
months recall period on the 15-point GRC for the SGRQ
was significantly higher in absolute value when comparing
with the estimates at three weeks and three months. How-
ever, an anchor question with only five answering options
did result in significantly absolute lower MCIDs for CAT
and CCQ in comparison with the 15-point GRC at
12 months. Estimates were − 1.4 for CAT (significant differ-
ence − 1.4), − 0.3 for CCQ (significant difference − 0.2), and
− 7.7 for the SGRQ (non-significant difference − 1.1).
Interpretation of findings
The MCID ranges found in the current study for both
CAT and CCQ were in correspondence with those avail-
able in the literature [21–28]. Recall periods on the an-
chor question of two to three days, three weeks and
eight weeks have been used before for CAT and CCQ
[21, 23, 25, 27, 28]. Most MCID estimates for the CAT
in the current study were significantly higher than the
two points threshold, which had been advocated using a
five point GRC scale [27, 28]. Since CAT only allows for
integer scores, a cut-off MCID of three points would be
suggested here. For the CCQ, all recall periods and an-
chor question types included the 0.40 points MCID as
reported in the literature, although our estimates were
closer to 0.50 points [21–26]. Both five-point and
15-point GRCs were used generating a 0.40 MCID esti-
mate for the CCQ [21, 23]. The estimates for the SGRQ
in the current study were significantly higher compared
with the existing four points MCID, which is used exten-
sively in scientific research [29, 31]. This MCID was
among others based upon a five-point question requiring
COPD patients to assess the treatment effects over a
16-week period. It did not require patients to assess
their experienced change in health status, hence may re-
sult in a different MCID. The current study provided
additional support to the recommendation by Welling et
Table 2 Health status baseline and change scores
N CAT CAT Standardized CCQ Total CCQ Total Standardized SGRQ Total
Change at discharge (T1) 451 − 3.1*
(− 3.6 to − 2.6)
− 7.8*
(− 9.1 to − 6.5)
−0.6*
(− 0.7 to − 0.5)
− 9.7*
(− 11.2 to − 8.3)
− 9.0*
(− 10.2 to − 7.9)
Change after 3 months (T2) 355 − 1.4*
(− 2.2 to − 0.7)
−3.6*
(− 5.4 to − 1.8)
− 0.3*
(− 0.4 to − 0.2)
− 4.3*
(− 6.2 to − 2.5)
− 5.4*
(− 6.9 to − 3.8)
Change after 6 months (T3) 319 −0.9*
(− 1.7 to − 0.1)
−2.3*
(− 4.2 to − 0.4)
− 0.1
(− 0.2 to zero)
−1.8
(− 3.8 to + 0.2)
− 4.9*
(− 6.5 to − 3.2)
Change after 9 months (T4) 304 −1.1*
(− 1.9 to − 0.4)
−2.9*
(− 4.8 to − 0.9)
− 0.2*
(− 0.4 to − 0.1)
− 3.8*
(− 5.8 to − 1.8)
− 5.2*
(− 6.9 to − 3.4)
Change after 12 months (T5) 309 −0.9*
(− 1.7 to − 0.1)
− 2.2*
(− 4.2 to − 0.3)
− 0.2*
(− 0.3 to − 0.1)
− 2.7*
(− 4.7 to − 0.7)
−3.9*
(− 5.7 to − 2.2)
Change scores reported as mean (95%CI). Change scores were calculated in comparison to baseline. Negative values represent improvement for CAT, CCQ and
SGRQ. CAT and CCQ were standardized into a scale from zero to 100 to be comparable with SGRQ
95% CI 95% Confidence Interval, CAT COPD Assessment Test, CCQ Clinical COPD Questionnaire, N Number of patients, SGRQ St. George’s Respiratory
Questionnaire, T1 Measurement at discharge, T2 3 months follow-up, T3 6 months follow-up, T4 9 months follow-up, T5 12 months follow-up
*Significance of change scores p < 0.05 at T1/T2/T3/T4/T5 compared to baseline (T0)
Table 3 Correlations between health status change scores and the Global Rating of Change anchor questions
15-point GRC T1 15-point GRC T2 15-point GRC T3 15-point GRC T4 15-point GRC T5 Five-point GRC T5
N of Patients 451 355 319 304 309 309
CAT change score − 0.23 − 0.33 − 0.40 − 0.43 − 0.41 0.46
CCQ total change score −0.29 − 0.42 − 0.44 −0.48 − 0.47 0.50
SGRQ total change score −0.30 −0.48 − 0.51 −0.58 − 0.54 0.57
Data reported as Pearson or Spearman correlation coefficients between the health status change scores and the anchor questions. Correlations ≥0.50 are
highlighted bold
CAT COPD Assessment Test, CCQ Clinical COPD Questionnaire, GRC Global Rating of Change scale, SGRQ St. George’s Respiratory Questionnaire, T1 Measurement
at discharge, T2 3 months follow-up, T3 6 months follow-up, T4 9 months follow-up, T5 12 months follow-up
Alma et al. Health and Quality of Life Outcomes  (2018) 16:130 Page 6 of 13
al. [30] and Alma et al. [25] that the MCID of the SGRQ
of four points should be set higher.
There was a remarkable significant difference between
the five-point and 15-point anchor question scale in esti-
mating the MCIDs for CAT and CCQ at 12 months, al-
though the Spearman correlation between both anchor
scales was strong. However, the classification of patients ac-
cording to both GRCs was only for 55% consistent, result-
ing thus in a different categorization of the degree of
change assessed by patients themselves. Although the
15-point GRC was analysed as a seven-point scale, the pa-
tients had 15 answering options to choose from, compared
with five on the other GRC. Too few reply options on an
anchor question might lead to loss of relevant information,
leading to less discriminative power and lower sensitivity
[9]. It may result into lower MCIDs. This seems to be the
case for the current study for both CAT and CCQ, and to a
lesser extent for SGRQ as well. Earlier studies used only
five-point GRCs for CAT and SGRQ [27–29, 31]. These
studies showed lower absolute MCIDs. A five-point anchor
Fig. 2 Correspondence between the five- and 15-point Global Rating of Change scale at 12 months follow-up
Table 4 MCID estimates for minimally improved patients as indicated on the GRC during follow-up
Measurement period N CAT CAT Standardized CCQ Total CCQ Total Standardized SGRQ Total
15-point GRC T1-T0 196 −3.1*±5.3
(− 3.9 to − 2.4)
− 7.8*±13.2
(− 9.7 to − 5.9)
−0.6*±0.8
(− 0.7 to − 0.4)
− 9.3*±14.0
(− 11.3 to − 7.3)
− 8.4*±11.8
(− 10.1 to − 6.7)
15-point GRC T2-T0 107 −2.7*±6.4
(− 4.0 to − 1.5)
−6.9*±16.1
(− 9.9 to − 3.8)
−0.4*±1.0
(− 0.6 to − 0.2)
− 7.3*±16.8
(− 10.5 to − 4.0)
− 7.6*±13.8
(− 10.2 to − 4.9)
15-point GRC T3-T0 96 − 2.7*±6.7
(− 4.1 to − 1.4)
−6.8*±16.7
(− 10.2 to − 3.5)
−0.4*±1.1
(− 0.6 to − 0.2)
− 7.0*±18.0
(− 10.6 to − 3.3)
− 9.2*±14.0
(− 12.1 to − 6.3)
15-point GRC T4-T0 80 −2.3*±6.1
(− 3.7 to − 1.0)
−5.8*±15.2
(− 9.2 to − 2.4)
−0.5*±0.8
(− 0.7 to − 0.3)
− 7.6*±13.8
(− 10.8 to − 4.7)
− 10.3*±12.9
(− 13.2 to − 7.4)
15-point GRC T5-T0 88 −2.8*±6.7
(− 4.2 to − 1.4)
−7.0*±16.7
(− 10.5 to − 3.5)
− 0.5*±1.0
(− 0.7 to − 0.3)
− 8.3*±16.3
(− 11.7 to − 4.8)
− 8.8*±14.1
(− 11.8 to − 5.8)
Five-point GRC T5-T0 81 −1.4*±5.9
(− 2.7 to − 0.1)
−3.5*±14.7
(− 6.7 to − 0.3)
−0.3*±0.8
(− 0.5 to − 0.2)
− 5.5*±13.8
(− 8.7 to − 2.5)
−7.7*±12.9
(− 10.5 to − 4.8)
Minimal change scores reported as mean ± SD (95%CI). Change is measured compared to baseline. Negative values represent improvement for CAT, CCQ and
SGRQ. CAT and CCQ were standardized into a scale from zero to 100 to be comparable with SGRQ
*Significance of change scores p < 0.05 at T1/T2/T3/T4/T5 compared to baseline (T0)
95%CI 95% Confidence Interval, CAT COPD Assessment Test, CCQ Clinical COPD Questionnaire, GRC Global Rating of Change scale, N number of patients, SD
Standard Deviation, SGRQ St. George’s Respiratory Questionnaire, T0 Measurement at baseline, T1 Measurement at discharge, T2 3 months follow-up, T3 6 months
follow-up, T4 9 months follow-up, T5 12 months follow-up
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scale may therefore not discriminate sufficiently. Kamper
S.J et al. recommended to include seven to 11 reply options
for optimal discrimination [9]. Another difference between
the current five-point and 15-point GRC was that the first
one was a verbal scale, while the latter one was a numeric
scale. Possibly this has influenced the classification as words
may result in a different perception in comparison to
numbers.
Using an anchor question to determine an instru-
ment’s MCID is common practice [6–8]. Jaeschke et al.
were the first to use this approach in determining the
MCID of the Chronic Respiratory Questionnaire (CRQ)
using a 15-point Likert scale GRC [5]. Since then many
have adopted this method, but have also applied alterna-
tive versions to determine the MCID. The approach is
easy to administer and the single best measure of the
significance of change from the patient’s perspective [9–
11]. However, anchor questions rely on the patient’s abil-
ity to recall their former health state [9–11]. Accurate
recall is determined by factors such as forgetting, more
recent (impactful) health events, and current mood state
[11]. Global Rating of Change scales may therefore not
provide an accurate reflection of the real experienced
change due to these recall biases.
It has been speculated that longer recall periods would
lead to less accurate estimates of change and even to differ-
ent MCIDs [10, 38–42]. Evaluation of change turned out to
be more correlated with the current health state and sever-
ity of experienced symptoms, rather than with the former
(baseline) condition [9, 10, 41–48]. There are, however, also
studies that did not find specific differences between recall
periods [39, 49–51]. There is no single optimal recall period














Mean change −3.1 −2.7 − 2.7 − 2.3 −2.8 −1.4
SD of the change 5.3 6.4 6.7 6.1 6.7 5.9
N of patients 196 107 96 80 88 81
ICC 0.7 0.6 0.5 0.6 0.5 0.6
Z score required 0.62 0.98 0.98 0.98 0.98 0.98
Standard Error 0.4 0.6 0.7 0.7 0.7 0.7




(− 8.4 to − 7.2)
−6.9




(− 7.4 to −4.1)
− 7.0
(− 8.8 to − 5.3)
− 3.5
(− 5.1 to − 1.90)
CCQ Total
Mean change −0.6 − 0.4 − 0.4 − 0.5 −0.5 − 0.3
SD of the change 0.8 1.0 1.1 0.8 1.0 0.8
N of patients 196 107 96 80 88 81
ICC 0.7 0.6 0.5 0.7 0.5 0.6
Z score required 0.62 0.98 0.98 0.62 0.98 0.98
Standard Error 0.1 0.1 0.1 0.1 0.1 0.1








(− 8.8 to −5.2)
−7.7
(− 8.7 to −6.7)
− 8.3
(− 10.0 to − 6.7)
− 5.5
(− 7.0 to −4.0)
SGRQ Total
Mean change −8.4 −7.6 − 9.2 − 10.3 −8.8 − 7.7
SD of the change 11.8 13.8 14.0 12.9 14.1 12.9
N of patients 196 107 96 80 88 81
ICC 0.7 0.7 0.7 0.7 0.6 0.6
Z score required 0.62 0.62 0.62 0.62 0.98 0.98
Standard Error 0.8 1.3 1.4 1.4 1.5 1.4
CI −8.9 to −7.9 −8.4 to −6.8 −10.1 to −8.3 −11.2 to −9.4 −10.3 to − 7.4 −9.1 to − 6.3
CAT COPD Assessment Test, CCQ Clinical COPD Questionnaire, CI Confidence Interval, GRC Global Rating of Change scale, ICC Intraclass Correlation Coefficient, N
Number of Patients, SD Standard Deviation, SGRQ St. George’s Respiratory Questionnaire, T0 Measurement at baseline, T1 Measurement at discharge, T2 3 months
follow-up, T3 6 months follow-up, T4 9 months follow-up, T5 12 months follow-up
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[39, 51]. The required window is dependent upon whether
or not acute effects need to be measured, whether acute
events occur, as well as the nature of the disease [39, 52].
Longer recall periods may therefore be appropriate for
chronic conditions with slow changes. It was argued that
the optimal length for measuring change on a PRO in
COPD would be six to 12 months [53]. A recall period of
more than one year could lead to problems due to the pro-
gressive nature of the disease. In addition to the impact of
recall bias, a patient’s evaluation of a specific health state
might change over time due to a response shift [54]. This
concept refers to a change in the meaning of the concept
HRQoL for the patient. Response shift was demonstrated
to have an influence on the MCID in HRQoL tools in
breast cancer research [55]. Evidence for the influence of
response shift as well as recall bias on the MCID of COPD
health status is currently absent in the literature.
The current study had a fixed recall moment, which was
related to the start of an intense PR program. The effects
of PR would be expected to remain over a longer period
of time, leading to less exacerbations and less acute
changes in the health state of the COPD patients [56].
Jones et al. [53] recommended measurement of PROs in
COPD over a 6–12 months period as the optimal recall
period, which our study did. The assessment of change
compared with the start of PR, the expected stability of
COPD symptoms over time after PR and the use of the
optimal recall period might help explain why this study
found stable MCID estimates during follow-up.
Correlations between the anchor question and the
health status change scores were sufficient to be used as
anchor, except for the three week measurement period. It
may, therefore, not be surprising that those estimates were
especially for CAT and CCQ higher than the other MCID
estimates. Evaluating change directly after an impacting
event, such as PR or exacerbations, could potentially bias
the MCID measurement of an instrument. The estimates
of the SGRQ seemed rather stable over time, perhaps be-
cause SGRQ is a more extensive and lengthier tool in
comparison to the CAT and CCQ.
Strengths and limitations
This is the first study to investigate the impact of the re-
call period of the patient’s GRC and its design on the
MCID for improvement of COPD health status tools. It
is to the best of our knowledge the only study, which
Fig. 3 MCID estimates with for dependency adjusted confidence intervals for CAT and CCQ total score. Data are presented as MCID estimates
(squares) and their respective confidence interval (horizontal line) adjusted for the dependency of the data. The red vertical lines represents the
MCID estimates for CAT and CCQ total score obtained from the literature. Negative values represent improvement in health status
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measured the MCID of CAT, CCQ and SGRQ in one
study over multiple study periods, and included a unique
test of significance for the MCID according to the
methods of Afshartous et al. [37]. In the current study,
MCIDs were tested over multiple periods of time. No
correction for multiple testing was made, risking an in-
crease in the probability to run a type I error. However,
since this was a diagnostic study, we considered this to
be of limited importance as there is no intention to
make a formal statement about efficacy or safety based
on hypothesis testing [57]. Furthermore, the confidence
intervals for the MCID estimates were adjusted for the
dependency of multiple follow-up data.
The results found in this study are valid for a PR setting.
As MCIDs may differ per setting, the results need not ne-
cessarily be valid in other populations [11]. However, our
results were in line with the existing MCIDs in the litera-
ture, which were also determined outside the field of PR.
MCIDs were determined based upon a patient’s perspective
of their health status change. No clinician, neither the pa-
tient, was involved to make a judgement about the clinical
relevance of the perceived change though. Correlations be-
tween the GRCs and the health status questionnaires were
sufficient according to pre-determined criteria, however in
fact these correlations are still only small to moderate.
Another limitation is that the data used in this study
were based on improvement only, as the number of pa-
tients deteriorating for each follow-up period was small to
allow for significance testing. MCIDs for improvement
may, however, differ from those for deterioration [11].
Furthermore, this study determined the MCID over differ-
ent recall periods using the 15-point GRC scale. The
five-point anchor question was, however, only measured
over a twelve month period. It would not be possible to
conclude whether recall bias occurred for a five-point
GRC. Last, the anchor-based MCID technique can be
considered a population-based figure, rather than a reflec-
tion of the individual’s change [6–8, 11]. This is a limita-
tion of the technique in itself. Using a larger sample
would lead to regression to the mean of the MCID esti-
mate, which is less subject to larger changes in an individ-
ual’s health state.
Implications for future clinical practice and theory
No other evidence exists for the impact of the recall
period and the design of the anchor question on the
Fig. 4 MCID estimates with for dependency adjusted confidence intervals for SGRQ total score including standardized estimates for CAT and CCQ
total scores. Data are presented as MCID estimates (squares) and their respective confidence interval (horizontal line) adjusted for the
dependency of the data. The red vertical line represents the MCID estimate for SGRQ total score obtained from the literature. Negative values
represent improvement in health status
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determination of MCIDs in COPD health status. Ideally,
more research is needed to confirm or falsify the current
findings in both a PR and other settings. It would be rec-
ommended to use multiple patient-referencing anchors
over multiple periods of time to carefully estimate an in-
strument’s MCID. Multiple MCIDs might potentially
apply to practice for different time periods of measure-
ment used in clinical trials. However, this study was the
first to suggest otherwise. It indicated a differentiation
might be needed between measurement of change dir-
ectly after an impacting event and in stable patients, as
this may be an important factor influencing recall bias.
Conclusions
Various recall periods on a 15-point anchor question seemed
not to be associated with systematic significant differences in
the MCIDs for improvement of the CAT, CCQ and SGRQ,
with the exception of the shortest 3-week measurement
period directly after PR for CAT and CCQ, which led to
absolute higher MCID estimates. Measuring change with a
shorter recall period directly after an impacting event might
potentially bias measurement. Using an anchor question with
less answering options over a one-year period of time in
determining an instrument’s MCID may also coincide with
(significantly) lower absolute MCID estimates as less dis-
criminative options might be available for the patient.
Additional file
Additional file 1: Figure S1. 15-point Global Rating of Change anchor
question used at each follow-up moment. Figure S2. Five-point Global Rating
of Change anchor question used at 12-months follow-up. (DOCX 163 kb)
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